- LOGIN
- MemberShip
- 2025-12-26 08:56:52
- Company
- Huons has secured domestic rights to Sputnik Light
- by Lee, Seok-Jun Jul 11, 2021 07:03pm
- Huons said on the 7th that it has secured exclusive rights to domestic licenses and sales of Russia's one-shot vaccine Sputnik Light. Sputnik Light will be produced from Huons Global Consortium starting from second half of this year. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology. It is a one-shot vaccine that was approved for use in Russia in May. It uses the same adenovirus as Sputnik V, a double inoculation method, as a vector (transmitter. However, only one type of vector (adenovirus type 26) needs to be inoculated once. The prevention effect is 79.4% and the immune system is known to last 3 to 4 months. Since the end of February, phase III has been underway for about 7,000 people in countries such as Russia, the United Arab Emirates and Ghana. Huons is considering Emergency Use Authorization for quick domestic approval.
- Company
- Researchers find COVID-19 Txs more effective than remdesivir
- by Kim, Jin-Gu Jul 09, 2021 05:56am
- A Korean research team of the Korea Advanced Institute of Science and Technology (KAIST) discovered new drug candidates for the treatment of COVID-19. Some of the candidates are expected to have a better effect than the currently approved remdesivir (product name: Veklury). On the 8th, the joint research team of Sang-yup Lee, Distinguished Professor of Chemical & Biomolecular Engineering at KAIST, and Dr. Seung-taek Kim, researcher of Institut Pasteur Korea (IPK)’s Zoonotic Virus Laboratory announced that they have discovered potential candidates for treating COVID-19 using their virtual screening technology. The team opted for a drug repurposing strategy using virtual screening. In other words, the team sought to find substances that may help treat COVID-19 among drugs with verified efficacy and safety. The researchers first built a virtual library on 6,218 drugs that are FDA-approved or in clinical trials, and then applied their newly developed virtual screening technology. The accuracy of the system was improved by adding structural similarity and interaction similarity analysis modules to the existing docking simulation-based virtual screening technology. Summary of the COVID-19 treatment development process using virtual drug screening technology (source: KAIST) Using the platform, the team selected 38 candidate compounds that inhibit the protease and RNA-dependent RNA polymerase needed for the replication and proliferation of the COVID-19 virus. Then, the efficacy of the candidates was verified by the Institut Pasteur Korea. Testing was conducted using a monkey’s kidney cells infected with COVID-19. Of the 38 candidates, 7 compounds showed antiviral activity. The 7 compounds that showed promise were further verified on human lung cells to be narrowed down to three: omipalisib, and tipifarnib, and emodin. Among these, omipalisib was found to have an antiviral activity that is over 200 times higher than that of remdesivir. Antiviral activity of tipifarnib was found to be similar to remdesivir. Omipalisib is currently being studied in a clinical trial as a treatment for cancer and pulmonary fibrosis. Tipifarnib is being studied in a clinical as a treatment for and progeria, and emodin, which is derived from plants, is being studied in a clinical trial as an anticancer drug. The research team is planning a preclinical trial on these 3 candidate substances. In the preclinical trial, the team aims to minimize toxicity and reach the effective concentration for treating COVID-19. Regarding the findings, Professor Sang-yup Lee said, ”With the research, we were able to prepare a base technology to promptly respond to new emerging viruses. We will continue our research to develop technologies applicable to new infectious viruses as well as variants of the coronavirus.”
- Company
- Jeil's anti-cancer drug business is doing well
- by Nho, Byung Chul Jul 08, 2021 05:59am
- It is noteworthy that Jeil is investing in expanding the lineup of anticancer drugs and research and development in related fields. Jeil, who entered his 33rd year of anti-cancer drug business, has a strategic relationship with Kyowa Kirin and Taiho in Japan and is making efforts to distribute original anti-cancer drugs. When the new anti-cancer drugs were introduced in the late 1980s, Jeil established a separate anti-cancer sales and marketing team to strengthen its professional capabilities and make communication between doctors and salespeople a top priority. The most likely anti-cancer drugs are Grasin300 PFS (Kyowa Kirin), Neulasta PFS(Kyowa Kirin), UFT(Taiho), Ts-1(Taiho), and Lonsurf (Taiho). The first anti-cancer drug introduced by Jeil was UFT(Tegafur·Uracil), which was first released in Korea in 1989. It is effective in relieving symptoms such as head and neck cancer, stomach cancer, rectal cancer, liver cancer, lung cancer, prostate cancer, uterine cervical cancer, and breast cancer, etc. UFT has capsule formulations and granules, which are usually administered three to six capsules a day, and the granules are taken in two to three doses of 300 to 600 mg. In 1993, Grasin300 PFS (Filgrastim) was released. The drug, which is a granulocyte colony-stimulating factor (GCSF) preparation, has indications of neutrophilosis, bone marrow dysplasia, regenerative anemia, congenital and idiopathic neutrophilia (HIV) infections. In 2004, the company launched a treatment called Ts-1(Gimeracil, Oteracil Potassium,Tegafur) for stomach, head and neck cancer, pancreatic cancer, and non-small cell lung cancer, providing a variety of treatment options for domestic patients. In 2014, it released Neulasta (Pegfilgrastim), the second generation G-CSF and co-sold it in Korea with Kyowa Kirin. Last year, Lonsurf (Tipiracil+Trifluridine) was introduced to provide new options for colon cancer treatment, and has continued its long sales experience in the domestic anticancer drug market. Lonsurf passed DC of 50 hospitals nationwide, including Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, and Severance Hospital in the first year of its launch. Based on UBIST, it ranks first in sales in the field of oral anticancer drugs newly approved in 2020, and is recognized for its efficacy. Lonsurf is expanding its share of the colon cancer market using a specialised sales network. Attention is also focusing on Onconic therapeutics, which was established last year to improve its position in the anti-cancer drug R&D field. Bio company Onconic therapeutics is a subsidiary 100% invested by Jeil and is expected to grow as an organization focused on the development of immune and targeted anti-cancer drugs. A year after its establishment, the company announced the results of Phase 1 for PARP (Poly ADP-ribose Polymerase) and JPI-547 at ASCO, drawing attention from Big Pharma. Phase I of the clinical trial evaluated the medicinal efficacy, safety of JPI-547 in patients with terminal solid cancer, according to Lim Seok-ah, a professor of hemato-oncology at Seoul National University Hospital, announced at the poster session. It is encouraging to identify the potential as a new treatment for ovarian cancer that does not respond to existing PARP treatments. Based on the results of this Effects are expected in HRD and PARP inhibitor resistant patients, including BRCA. "Based on the 30-year history of introducing anti-cancer drugs, we are continuously expanding our specialized sales network in related fields." said a representative of Jeil. "We will strengthen the pipeline of new items and improve our long-term research and development capabilities in the anticancer drugs market through open collaboration with Onconic Therapheutics."
- Company
- Chong Kun Dang loses 1st substance patient suit on ‘Xarelto
- by Kim, Jin-Gu Jul 08, 2021 05:58am
- Pic. of Xarelto Chong Kun Dang has lost its first trial targeting the substance patent of Bayer’s new oral anticoagulant (NOAC) ‘Xarelto(rivaroxaban).’ Whether Chong Kun Dang will modify its strategy to preoccupy the market through a release of its generic before substance patent expiry due to this ruling is gaining attention. On the 6th, the Intellectual Property Trial and Appeal Board (IPTAB) has ruled in favor of the original manufacturer Bayer, in a trial to confirm the passive scope of rights for Xarelto’s substance patent that was filed by Chong Kun Dang. Chong Kun Dang had solely challenged Xarelto’s substance patent in December last year. This was interpreted as a strategy made to overtake SK Chemicals and Hanmi Pharmaceutical that is currently leading the Xarelto generic market. SK Chemicals and Hanmi Pharmaceutical were the first to succeed in avoiding Xarelto’s formulation patent. The two companies finally won in December last year after the case went up to the Supreme Court, and secured exclusive marketing approval for Xarelto's 2.5mg formulation. However, both companies were unable to overcome the substance patent, and are unable to release the generic version until Xarelto’s substance patent expires in October this year. Chong Kun Dang made the bid for victory by challenging Xarelto’s substance patent. Then, in May, the company released its Xarelto generic 'Riroxia Tab.' 15mg and 20mg' in the market, before Xarelto’s substance patent expires. This was an attempt to preoccupy the market alone by avoiding the substance patent. Chong Kun Dang’s bold attempt was considered a risky game - if the company wins the case, the early release of its generic will not have constituted a patent infringement, but if it oses, it could bring serious repercussions from patent infringement. However, Chong Kun Dang lost the first trial. Based on the current situation, it has been analyzed that Chong Kun Dang's risky attempt is highly likely to fail and that Chong Kun Dang will have to bear the burden of patent infringement. For now, Chong Kun Dang is highly likely to appeal the case, as the higher courts may decide otherwise. Some industry officials also believe that even if Chong Kun Dang loses in the end, the end results will not be bad in terms of profit or loss. An official explained, “From Chong Kun Dang’s view, the profit gained by preoccupying the market while the patent suit is reviewed by higher courts may be greater than the compensation for damages that the company will owe to Bayer from the patent infringement."
- Company
- GC Pharma, the most likely company to produce Covivak
- by Nho, Byung Chul Jul 08, 2021 05:58am
- Chumakov Institute recently visited Andong Animal Cell Verification Support Center. Russia's Covivak is likely to be produced in domestic CMOs. According to industries, MPC, which is a South Korean corporation to introduce Covivak, recently signed a contract with Pharm Bio-tech, a Russian company that has rights to produce and publish in Russia, to acquire shares (37.5%). Among the domestic companies that invested in securing the stake, Wellbiotec, HumanN, and Nexton Bio became Pharm Bio-tech shareholders. MPC is also expected to establish a joint venture for Pharm Bio-tech and Covivak production, sales, and distribution in Korea to run vaccine businesses for ASEAN countries. The fact that it has become the second largest shareholder of Pharm Bio-tech, which has Covivak production and copyright, is interpreted as including technology transfer conditions, not just CMO production. It can also secure dividends based on sales performance of vaccine exports. This is in contrast to Samsung Biologics' production of Moderna COVID-19 vaccine CMO, which has yet to be confirmed whether or not the technology will be transferred. GC Pharma and Andong Animal Cell Demonstration Support Center are among the CMO and CDMO pharmaceutical bio companies that will produce Covivak. According to industry estimates, it takes about two months for the technology transfer of the Chumakov Institute researchers at the Russian Federal Academy of Sciences, and is likely to be completed by September at the latest. It is expected that production of Covivak will be possible around October. MPC, which is in charge of South Korea's Covivak business, said, "It is difficult to answer questions related to consignment production, consignment development and production." "However, all companies that are interacting agree that South Korea should become a global outpost for producing COVID-19 vaccines, and we will be able to produce positive results."
- Company
- Y-Biologics has transferred anti-cancer drug technology
- by An, Kyung-Jin Jul 08, 2021 05:58am
- Y-Biologics announced on the 6th that it has signed a license agreement with French pharmaceutical group Pierre Fabre for antibody candidates. The deal is worth up to 116.4 billion won, including upfront fee and Milestone. Under the deal, Y-Biologics grants Pierre Fabre the right to exclusively develop and commercialize YBL-003, which has been developed for solid cancer treatment purposes worldwide. YBL-003 is a type of Checkpoint inhibitor that controls macrophage function and T-cell activity to reactivate the immune system of the tumor microenvironment and kill cancer cells. It is an early-stage leading material, and milestones can occur whenever the development of YBL-003, such as preclinical and clinical, proceeds and reaches commercialization goals. Technical fees for sales are guaranteed separately. However, detailed contract terms such as initial down payment were not disclosed. Industry sources say that the license contract for YBL-003, which is an early stage of development, could be concluded because the two companies maintained a close cooperative relationship while conducting joint research since last year. They have agreed to study three targets every year and jointly study and transfer up to 15 targets during the contract period. The joint research contract between the two companies is three years, and the contract can be extended for the next two years. YBL-003 is considered highly likely to be used as an immune anticancer drug for solid cancer targets as it can expand its adaptations to stomach, lung and breast cancer. Pierre Fabre plans to develop a new design drug optimized for tumor treatment through preclinical and clinical development after the introduction of YBL-003. This contract is the first of 15 targets, and there is a possibility that additional contracts will be made in the future. Pierre Fabre is the second largest pharmaceutical group in France. Last year's sales amounted to 2.3 billion euros. Recently, while adjusting R&D priorities, it has focused on apothecary fields such as targeted treatment and immuno-tumorology. In addition to colon cancer, breast cancer, lung cancer, and melanoma, it is known that there is a high interest in pre-cancer diseases such as photokeratosis. Y-Biologics is a bio-venture that specializes in developing antibody new drugs based on its own platform. It was founded in 2007 by Dr. Park Young-woo, who has been working on antibody new drugs for 20 years in LG Life Sciences. It is discovering and developing various pipelines based on original technologies such as more than 100 billion kinds of human antibody library "Ymax-ABL" and dual antibody platform "ALiCE". It is currently in the process of listing on KOSDAQ through technical specials within this year. Earlier this year, it passed the screening, receiving A ratings from two professional evaluation agencies designated by the Korea Exchange, and filed a preliminary review of KOSDAQ listing in May. Park Young-woo, CEO of Y-Biologics, said, "I am very happy to sign the first license agreement with Pierre Fabre. As joint research is underway on another innovative target, we expect cooperation between the two companies to further develop innovative immune tumor treatments targeting the tumor microenvironment."
- Company
- MFDS in a month-long silence regarding Champix issue
- by Jul 07, 2021 05:54am
- Confusion in the field continues as the impurity issue of the smoking cessation treatment ‘Champix(varenicline)’ remains unresolved. Contrary to the U.S. and Canada, where the authorities preemptively provided guidelines to patients and HCPs while notifying them of the product recall and the possibility of impurities, the Korean health authorities have kept their silence for over a month. The Ministry of Food and Drug Safety had ordered Champix manufacturer Pfizer and other domestic manufacturers to investigate the impurities earlier last month. However, this fact was not publicly announced by the authorities and was disclosed through Dailypharm’s report on the 14th of last month. Pfizer had first stopped the supply of Champix, however, confusion remains in the field. The official notice that Pfizer had sent to distributors on the 11th last month did not indicate any possibility of impurities. In the notice, Pfizer wrote, “The product is out of stock due to supply shortage. We are experiencing a shortage due to disruptions in global distribution. We expect to resume supply from mid-July (subject to change).” An official from the distributing industry said, “We became aware of the impurity issue through the news article. We are still unsure whether to sell or keep the current inventory, and whether resupply will be possible from mid-July. We asked Pfizer directly but didn’t get a clear answer.” On this, an official from Pfizer said, “(The reason for not specifying the possibility of impurities) We were focusing on notifying the distributors of the shortage in supply.” The official continued, “We are doing our best to address the situation, from inspecting for impurities to preparing follow-up measures.” However, a month has passed since the issue arose, and still no guideline has been issued for the prescription and intake of Champix to inform patients and HCPs. This is in stark contrast to how the U.S. and Canada provided guidelines while announcing the recall due to concerns over impurities. On the 8th and 30th of last month, Canadian health authorities had advised HCPs to “Not dispense the 5 lots of Champix that were affected due to the potential safety risk posed by long-term exposure to this impurity, and consider using available alternative products on the market,” while announcing the recall of Champix due to safety concerns. On the 2nd of this month, the U.S. FDA has also alerted people of the” voluntary recall of nine lots of Champix.” The FDA advised “healthcare professionals to consider other available treatment options for the patient’s medical condition,” and that “patients should continue taking their current medicine until their doctor or pharmacist gives you a replacement or a different treatment option.” In addition, the FDA recommended Pfizer revise its recall to the consumer level so that medical institutions and patients may request a refund for the Champix currently in the market.” However, Korea’s MFDS has not announced any official position on this matter. This lead to patients newly being prescribed the drug even after the issue rose to the surface. “I only became aware of the impurity concern in an article after being prescribed the drug. I am taking medications for hyperlipidemia, so I specifically asked my doctor about precautions when taking the drug, and the doctor assured me there was no issue. I believe the doctor wasn’t aware of this impurity issue either. With no guidelines set on this matter, I am not sure whether I should start taking the Champix I was prescribed or not,” said one patient. It is yet unclear at which stage the 'N-nitroso-varenicline' impurity detected in Champix occurred, and what the standards are. Also, whether the problem is limited to some lots (manufacturing unit), or is an issue for the formulation itself that contains varenicline is uncertain.
- Company
- [Reporter's view] Korean patients to name specific drugs
- by Eo, Yun-Ho Jul 07, 2021 05:54am
- A growing number of patients are looking for specific "Rx drugs." Patients who wanted certain OTC by visiting pharmacies are now finding a doctor and wanting certain Rx drugs. It is said that the demand for prescription, which was made in the past in the line of original and generics, is even spreading to the area of anticancer drugs. Times have changed. Patients or their families are now searching for new drugs or the clinical trial database (clinicaltrial.gov). When domestic licensed drugs are not covered by insurance benefits, complaints are poured out to the HIRA, the MOHW. Cheongwadae's petition is no exception. A professor at a university hospital said, "Patients already know the concept of reimbursement and non-reimbursement, and they demand a combination of prescriptions for the drugs. Of course, I try to reflect the patient's expression as much as possible, but sometimes I'm embarrassed by ridiculous demands." For example, diabetes patients who were taking Sulfonylurea are asking for DPP-4 inhibitors or hypertension patients who were taking ARB single drugs are actually asking for prescription of ARB+CCB complex drugs. But the right to prescribe Rx is a doctor's own right. The public has delegated them to doctors with expertise for their health. Even if the public's level of knowledge is high and there is distrust in the current medical society, the prescription of Rx drugs should be prioritized by professionals' medical judgment.
- Company
- The NPS bought shares in Samsung BioLogics & SK Bio
- by Kim, Jin-Gu Jul 06, 2021 05:51am
- The National Pension Service (NPS), the nation's largest institutional investor, significantly reduced its investment in the local stock market in the first half of last year. Investment in pharmaceutical bio stocks has rather increased. Investments in Samsung BioLogics, SK Bioscience, and SK Biopharm were significant. It sold more than ₩300 billion in shares of Celltrion. According to the KRX on the 5th, The NPS bought Samsung BioLogics shares worth ₩586.4 billion in the first half of this year. Not only pharmaceutical bio shares but also all stocks ranked first in net buying. The NPS' stake in Samsung BioLogics rose 0.12%p to 5.10% at the end of June from 4.98% at the end of last year. As of the end of June, Samsung BioLogics' stock valuation held by the NPS is close to ₩3 trillion as of the closing price of the 5th. In addition to Samsung BioLogics, four out of the top 10 net purchases of the NPS were pharmaceutical bio shares. SK Bioscience (3rd), SK Biopharm (6th), and Celltrion Healthcare (9th) ranked high. Net purchases of The NPS amounted to ₩259.1 billion from SK Bioscience, ₩157.6 billion from SK Biopharmaceutics, and ₩116.4 billion from Celltrion Healthcare. In addition, it sold ₩69.3 billion in GC LabCell shares, ₩49.5 billion in Hanmi Science, ₩45.2 billion in Daewoong Pharmaceutical, ₩41.6 billion in LegoChem Bioscience, ₩36 billion in Hugel, ₩35.5 billion in Medy Tox, ₩35.3 billion in ST PharmaReaserch, ₩26.2 billion in Celltrion, PharmaReaserch ₩17.5 billion in Pharmicell, ₩15.6 billion in Dong-A Socio Holdings, ₩15.2 billion in Alteogen, ₩13.4 billion in Daewoong, ₩12.5 billion in Macrogen, and ₩12 billion in Huons Global. The NPS' share of these companies has also increased. GC LabCell increased 1.12%p (4.99%→6.11%), Dewoong increased 1.05%p (5.09%→6.14%), and Hanmi increased 2.02%p (6.84%→8.86%). The NPS is said to have continued its all-time selling spree in the domestic stock market in the first half of this year. Net sales in first half of this year alone amount to ₩24.598 trillion. According to the fund management guidelines, the government decided to lower the portion of investment in domestic stocks to 16.8% by the end of this year, leading to large-scale net selling. As of the end of last year, it had a share of 21.2%. However, investment in pharmaceutical bio shares has increased even among large net sales. The cumulative net purchase amount of pharmaceutical bio shares by June is estimated at ₩836.7 billion. The NPS sold Celltrion shares the most. It bought ₩1.1447 trillion for six months and sold ₩1.507 trillion, reaching ₩362.3 billion in accumulated net sales. The NPS sold ₩182.8 billion in shares of SK Chemical, ₩85.5 billion in GC Pharma shares, ₩46 billion in Bukwang shares, ₩28.9 billion in JW-Lifescience shares, ₩28.4 billion in Chong Kun-dang shares, ₩24.5 billion in G-TreeBNT shares, ₩18.8 billion in Seegene shares and ₩15 billion in Shin Poong. Celltrion shares in the NPS fell 0.88%p to 7.48% at the end of June, compared with 8.36% at the end of last year. SK Chemical's shares fell 3.99%p from 10.13% at the end of last year to 6.14% at the end of June. In addition, shares of GC Pharma fell 0.04%p (9.12%→9.08%) and shares of Bukwang fell 1.12%p (8.18%→7.06%) respectively.
- Company
- Hemlibra & Afstyla were released
- by Kim, Jin-Gu Jul 06, 2021 05:50am
- Domestic pharmaceutical companies have challenged the hemophilia treatment market one after another. JW Pharma released Hemlibra and SK Plasma released Afstyla in the last year. The domestic hemophilia treatment market is maintained by GC Pharma and Takeda. While Bayer, Sanofi, and Pfizer, which have challenged the market in the past, are struggling, attention is focusing on whether domestic pharmaceutical companies will produce meaningful results. ◆GC Pharma is virtually monopolizing the domestic market with a size of ₩230 billion According to the pharmaceutical industry on the 30th, SK Plasma started selling Afstyla to major general hospitals in South Korea after entering its benefit early this month. SK Plasma is a company that specializes in blood products that were separated from SK Chemical in 2015. In 2009, SK Plasma exported the drug, which was a candidate material at the time, to Australian pharmaceutical company CSL Behring. The development was completed by CSL Behring. SK Plasma CEO Kim Yun-ho (left) and CSL Behring Korea CEO Son Ji-young are signing a sales contract for Afstyla Prior to SK Plasma, JW Pharma has entered this market. JW Pharma was approved by Japan's Chugai Pharmaceutical in January 2019. It released its products in earnest in May last year. The two companies should target the hemophilia treatment market, which is dominated by the GC Pharma. The domestic hemophilia drug market is effectively monopolized by GC Pharma. GC Pharma co-sells its own items, GreenMono and Greenene F, as well as Takeda's Advate and Adynovate. They are all top sales products. Pharmaceutical industries estimate size of South Korea's hemophilia treatment market is about ₩230 billion. Among them, four products sold by GC Pharma are estimated to generate sales of ₩140 billion to ₩150 billion. ◆ Hemophilia medicine must be passed by the committe of the Korea Hemophilia Foundation Pfizer, Sanofi, Bayer and others challenged this market before JW Pharma and SK Plasma. Except for Pfizer, however, their performance does not meet expectations. This is because the proportion of prescriptions through the Korea Hemophilia Foundation is large. The Korea Hemophilia Foundation, which consists of patients with hemophilia, operates a separate drug review committee. This Committee shall deliberate on medicines that may be prescribed by members of the Foundation. It is necessary to pass this committee to prescribe. The drugs currently being prescribed by an associate doctor are Adynovate and Adynovate in Takeda, GreenMono in GC Pharma, Greengene F and Xyntha Solofuse in Pfizer. Bayer's Kogenate FS and Sanofi's Eloctate failed. Kogenate FS and Eloctate are prescribed only in general hospitals, which account for 40% of the total market. Bayer and Sanofi are not making as much sales as expected. Pfizer's Xyntha Solofuse took nearly five years to be reviewed after its release in 2014. "The domestic market for hemophilia is called the tomb of a new drug," said PM, a global pharmaceutical company. "That's how hard it is to overcome the wall of the Korea Hemophilia Foundation." ◆JW Pharma and SK are targeting general hospitals first In the case of Hemlibra and Afstyla, sales can be stable only after passing the Korea Hemophilia Foundation's deliberation committee in the long term. The two companies are not planning to directly target the Korea Hemophilia Foundation. JW Pharma emphasizes the advantages of SC (subcutaneous) injection for general hospitals and it emphasizes that administration is possible regardless of whether antibodies are produced or not. Patients also have high expectations for this. Hemlibra is the first SC formulation. Existing patients had to find their own veins and inject themselves. Moreover, many of the patients were children, making them uncomfortable. JW Pharma said it is convenient to inject under the skin, not by finding and injecting blood vessels on its own. Hemlibra has limited benefit standards. The National Assembly pointed out, and the MOHW said it would reconsider expanding the benefit range. SK Plasma is planning to focus on targeting general hospitals. SK Plasma is said to have started marketing activities at major general hospitals at the time of the release of Afstyla. "We have no specific plans right now, such as sponsorship for the Korea Hemophilia Foundation," an official at SK Plasma said. "We plan to focus on expanding our influence in general hospitals."
